The world’s leading health organizations supporting celiac disease awareness and education (Celiac Disease Foundation, American Celiac Disease Alliance, Celiac Sprue Association, Gluten Intolerance Group and the National Foundation for Celiac Awareness) applaud the efforts of Alvine Pharmaceuticals and AbbVie in addressing the significant unmet medical need for therapeutic treatment of celiac disease. ALV003 is an investigational oral therapy composed of two recombinant, gluten specific enzymes (a cysteine protease (EP-B2) and a prolyl endopeptidase (PEP)), that degrade gluten in-vitro and in human clinical testing, and may reduce the symptoms and intestinal injury associated with celiac disease in patients attempting to adhere to a gluten-free diet.
5/14/2013
Progress Toward Oral Therapy for Celiac Disease
Recent Posts
- Ice Skating for Change: How One Inspiring Tween is Raising Awareness for Celiac Disease on Ice
- argenx Announces Positive Top-Line Results from Phase 2 Study of Investigational Celiac Disease Treatment
- New Study Quantifies Gluten Cross-Contact Risk in Shared Fryers
- First Tracks Biotherapeutics Announces Positive Top-Line Phase 1 Cohort 1 Results for Investigational Celiac Disease Treatment
Search the archive
Categories
- Advocacy News
- Celiac Disease in the News
- Clinical Trials
- Community Spotlight
- Eat! Gluten-Free
- Featured
- Foundation Press
- iCureCeliac
- Impact Fund
- Marilyn’s Message
- Monthly eNewsletter
- Patient Profile Advocacy Series
- Recipes
- Research
- Research News
- Trending Topics
Marilyn's Message
3/18/2025
Read moreA Bold New Look for the Celiac Disease Foundation
Dear Celiac Disease Foundation Community, For more than three decades, the Celiac Disease Foundation has been dedicated to improving the lives of those affected by celiac disease through research, advocacy, and education. What began as a grassroots effort has grown into a global organization, leading the charge in accelerating diagnosis,...